Abstract
Introduction: Pulmonary nodules, which are increasingly detected through computed tomography screening, currently lack optimal management options, particularly for small or benign lesions, for which surgical resection risks overtreatment and pharmacotherapy demonstrates limited efficacy. Objective: This study aims to validate Puling Yin (a 15:1 Taraxacum mongolicum/Ganoderma lucidum decoction) as a synergistic traditional Chinese medicine strategy for treating pulmonary nodules. Methods: The efficacy and safety of Puling Yin were evaluated using an in vivo pulmonary nodule model induced by Lewis. The synergy between T. mongolicum and G. lucidum was confirmed in vitro through CompuSyn analysis. Mechanistic insights were investigated using network pharmacology to identify overlapping targets. In addition, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was employed to identify key signaling pathways, and molecular docking was used to assess the binding affinity of bioactive compounds to core targets. Results: Puling Yin significantly reduced Lewis-induced pulmonary nodules by 66% (52.50 ± 21.23 vs. 153.67 ± 40.62 nodules/lung in the control) without observable toxicity. CompuSyn analysis confirmed a synergistic interaction enabling lower effective doses of T. mongolicum and G. lucidum. Moreover, network pharmacology identified 701 overlapping targets, and KEGG enrichment analysis highlighted the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway as a central pathway. Molecular docking revealed high-affinity binding of key bioactives, such as indolelactic acid, to AKT serine/threonine kinase 1 (−9.8 kcal/mol), demonstrating simultaneous interference with inflammation, immune response, and proliferation pathways. Conclusion: Puling Yin effectively suppresses pulmonary nodules through synergistic multi-target actions that holistically modulate the nodule microenvironment, with its key bioactives contributing to therapeutic efficacy by targeting critical pathways, including the PI3K/AKT signaling pathway.